|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1399 New York Avenue NW |
Address2 | Suite 600 |
| City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401049961-12
|
||||||||
|
6. House ID# 422720000
|
||||||||
| TYPE OF REPORT | 8. Year | 2015 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Paul Ehrlich |
Date | 10/19/2015 4:47:58 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R.2029, Military Construction and Veterans Affairs and Related Agencies Appropriations Act;
H.R. 3547, Consolidated Appropriations Act of 2014;
Other Labor, Health and Human Services Appropriations (No Bills Introduced);
H.R. 1078, Food & Drug Administration Safety Over Sequestration Act;
S. 1413, FDA User Fee Protection Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catherine |
Ferguson |
|
|
|
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 3116, MODDERN Cures Act of 2013;
S. 3004, Dormant Therapies Act of 2014;
H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015;
H.R. 1537 & S. 1878, Advancing Hope Act of 2015;
S. 632, STRONG Patents Act of 2015;
H.R. 9, Innovation Act;
H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015;
Proposals/Initiatives related to international intellectual property protection;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Health & Human Services - Dept of (HHS), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Catherine |
Ferguson |
|
|
|
Michael |
Boyd |
|
|
|
Stephen |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 6, 21st Century Cures Act;
Discussions to clarify or reform the 340B program;
Biologics Price Competition and Innovation Act;
H.R. 2031, TEST Act;
H.R. 1101 & S. 1287, Viral Hepatitis Testing Act;
Public Law 111-148, The Patient Protection and Affordable Care Act;
Implementation of The Prescription Drug User Fee Act (PDUFA);
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Boyd |
|
|
|
Catherine |
Ferguson |
|
|
|
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Stephen |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Policies to enhance patient access to medicines in Medicaid;
Policies to enhance patient access to medicines in Medicare;
H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act;
H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015;
H.R. 3261 & S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015;
H.R. 3261 & S. 1884, Medicare Prescription Drug Savings and Choice Act of 2015;
S. 2023, Prescription Drug Affordability Act of 2015
Medicare payment proposals;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Stephen |
Scango |
|
|
|
Catherine |
Ferguson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 880, American Research and Competitiveness Act of 2015;
H.R. 1430, Permanent CFC Look-Through Act;
S. 2260, Expiring Provisions Improvement, Reform, and Efficiency (EXPIRE) Act of 2014;
Innovation Promotion Act of 2015 (Not yet introduced);
Administrations Tax Reform and 2015 Budget Proposals;
Senate and House Committee Tax Reform Proposals;
Proposals to reform domestic and international tax structures (no bills introduced);
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Boyd |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
John |
Ford |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trans-Pacific Partnership Agreement;
Trade Promotion Authority;
H.R. 1890 & S. 995, Bipartisan Congressional Trade Priorities and Accountability Act of 2015;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catherine |
Ferguson |
|
|
|
Andrew |
Kaplan |
|
|
|
Michael |
Boyd |
|
|
|
John |
Ford |
|
|
|
Steven |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |